Traditional Chinese Medicine Xihuang Wan Inhibited Lewis Lung Carcinoma in a Syngeneic Model, Equivalent to Cytotoxic Chemotherapy, by Altering Multiple Signaling Pathways

Zhiying Zhang,Jianfeng Wang,Hua Duan,Dianna Liu,Xiangnan Zhou,Ximing Lin,Haoyue Pang,Manqiang Sun,Tian Zhou,Robert M Hoffman,Kaiwen Hu,ZHIYING ZHANG,JIANFENG WANG,HUA DUAN,DIANNA LIU,XIANGNAN ZHOU,XIMING LIN,HAOYUE PANG,MANQIANG SUN,TIAN ZHOU,ROBERT M. HOFFMAN,KAIWEN HU

DOI: https://doi.org/10.21873/invivo.12469

2021-01-01

In Vivo

Abstract:BACKGROUND/AIM: Xihuang Wan (XHW), a traditional Chinese medicine (TCM), has been used in China for a variety of cancers including lung cancer. The present study evaluated the efficacy of XHW on a Lewis lung mouse model and explored the potential mechanism via transcriptomics.MATERIALS AND METHODS: The mice were randomized into 6 groups: 1) untreated control (n=10); 2) low-dose XHW; 3) medium-dose XHW; 4) high-dose XHW; 5) cisplatin; and 6) untreated blank (n=4). Lewis lung carcinoma (LLC) cells were injected subcutaneously except for the 4 mice in the blank group. The body weight and tumor length and width were measured every 3 days. RNA-sequencing was performed on tumors in the high-dose XHW group and the control group.RESULTS: XHW inhibited the growth of LLC in a syngeneic mouse model, without toxicity, with equivalent efficacy to cisplatin. RNA-sequencing demonstrated that many signaling pathways were involved in XHW-mediated inhibition of LLC, including tumor necrosis factor, estrogen, cyclic guanosine 3', 5'-monophosphate-protein kinase G, apelin and the peroxisome proliferator-activated receptor signaling pathways.CONCLUSION: XHW inhibited LLC carcinoma through different pathways and shows clinical promise for patients who cannot tolerate platinum-based drugs.

medicine, research & experimental